ArticleJPGN reports2026
The 'Cross-Trust' Histopathology Multidisciplinary Team: Report of meeting outputs and impact on paediatric inflammatory bowel disease management in a UK tertiary centre.
Article in JPGN reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the outputs and clinical impact of a Cross-Trust Histopathology Multidisciplinary Team (MDT) created to support diagnostic clarification and management of complex paediatric inflammatory bowel disease (IBD) cases, particularly during transition to adult services. Methods: A retrospective review of eight MDT meetings held from January 2021 to March 2024 was performed. Patients were included if referred for diagnostic uncertainty, complex disease behaviour or transition planning. Extracted data included demographics, reason for referral, MDT-agreed diagnosis, therapeutic recommendations and transition-related decisions. Results: Twenty-seven patients (mean age 17.2 years; range: 14-21) were discussed. Diagnostic clarification was the primary referral reason. Following MDT review, 11 patients (41%) had a change in diagnosis, including reclassification of IBD-unclassified to ulcerative colitis ( Conclusion: The Cross-Trust Histopathology MDT improved diagnostic precision in complex paediatric IBD and influenced management in selected cases. The model supports harmonized interpretation across paediatric and adult services and promotes safer transition planning. Documentation of MDT outcomes remains an area for improvement. Wider adoption of similar collaborative frameworks may enhance diagnostic consistency and optimize care for adolescents with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.